Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTacP (Changchun BCHT)
- Development stage
- Unknown
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTacP is an adsorption-free, three-component acellular pertussis, diphtheria, and tetanus (DTaP) combined vaccine developed by Changchun BCHT Biotechnology. Unlike conventional DTaP vaccines that typically use aluminum-based salts as adjuvants (a process known as adsorption), this formulation is designed to be adsorption-free, which may potentially reduce local injection site reactions such as redness and swelling. The vaccine is intended for the active immunization of infants and young children to prevent diphtheria, tetanus, and pertussis. The "three-component" designation specifically refers to the acellular pertussis antigens included in the formulation, which typically comprise pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (PRN).
- Other names
- Adsorption-free DTaP vaccineAdsorption-free diphtheria and tetanus (three-component) combined vaccineDTaP-Changchun BCHT Biotechnology Co.-pertussis-diphtheria-tetanus
02
Targets
PRN (Pertactin)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTacP (Changchun BCHT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTacP (Changchun BCHT).